| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
1-Methylguanidine hydrochloride does not have a specific pharmacological target as it is an endogenous metabolite and research chemical. It is used as a building block in chemical synthesis. As a guanidine derivative, it may interact with various enzymes or receptors, but specific targets are not well defined.
|
|---|---|
| ln Vitro |
In vitro activity of 1-Methylguanidine hydrochloride is not evaluated as a bioactive compound with pharmacological effects. Its utility lies in its role as a chemical building block and endogenous metabolite. It can be used to prepare biaryl derivatives as BACE1 inhibitors and modified xylose for biodegradable composite hydrogels.
|
| ln Vivo |
In vivo, 1-Methylguanidine hydrochloride is an endogenously produced metabolite. It is not a therapeutic agent but is studied in the context of metabolism. Its levels in biological samples may reflect metabolic activity or alterations in disease states.
|
| Enzyme Assay |
In vitro enzyme assays with 1-Methylguanidine hydrochloride typically involve studying enzymes that recognize guanidine derivatives or methylated compounds. The compound can be used as a substrate or inhibitor in assays to characterize enzyme activity. Standard assays involve incubating with enzyme preparations and analyzing products by chromatographic methods.
|
| Cell Assay |
1-Methylguanidine hydrochloride is not typically used in cell culture experiments as a bioactive compound for treating cells. However, it may be employed in studies investigating guanidine metabolism or as a chemical tool. Its primary use is as a research chemical and building block for synthesis.
|
| Animal Protocol |
In vivo animal experiments with 1-Methylguanidine hydrochloride are not commonly performed as the compound is an endogenous metabolite and research chemical. If used, it would be to study guanidine metabolism or to validate analytical methods. Its primary significance is in research as a chemical building block.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of 1-Methylguanidine hydrochloride are not characterized as the compound is a metabolite rather than a drug. As a small, polar molecule, it is expected to be readily excreted. Specific PK data are not available in the literature.
|
| Toxicity/Toxicokinetics |
1-Methylguanidine hydrochloride has a low toxicity profile as an endogenous metabolite. It is not considered a hazardous substance. For research use, standard laboratory safety practices are sufficient. Comprehensive toxicology studies have not been published for this compound.
|
| Additional Infomation |
1-Methylguanidine hydrochloride belongs to the guanidine class of compounds.
1-Methylguanidine hydrochloride is a member of the guanidines and an endogenously produced metabolite. It can be used to prepare biaryl derivatives as BACE1 inhibitors and modified xylose for biodegradable composite hydrogels. The compound is not a drug and has no therapeutic indications. It is available for laboratory research use only. |
| Molecular Formula |
C2H8CLN3
|
|---|---|
| Molecular Weight |
109.56
|
| Exact Mass |
109.041
|
| CAS # |
21770-81-0
|
| PubChem CID |
146724
|
| Appearance |
White to off-white solid powder
|
| Density |
1.22 g/mL at 20 °C(lit.)
|
| Boiling Point |
72 °C
|
| Melting Point |
-20 °C
|
| Flash Point |
65 °F
|
| Index of Refraction |
n20/D 1.4279(lit.)
|
| LogP |
1.092
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
6
|
| Complexity |
42.9
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN=C(N)N.Cl
|
| InChi Key |
VJQCNCOGZPSOQZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C2H7N3.ClH/c1-5-2(3)4;/h1H3,(H4,3,4,5);1H
|
| Chemical Name |
2-methylguanidine;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 250 mg/mL (2281.85 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (912.74 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 9.1274 mL | 45.6371 mL | 91.2742 mL | |
| 5 mM | 1.8255 mL | 9.1274 mL | 18.2548 mL | |
| 10 mM | 0.9127 mL | 4.5637 mL | 9.1274 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
